Quantification of pancreatic exocrine function with secretin-enhanced magnetic resonance cholangiopancreatography: normal values and short-term effects of pancreatic duct drainage procedures in chronic pancreatitis. Initial results.
The aim of this study was to quantify pancreatic exocrine function in normal subjects and in patients with chronic pancreatitis (CP) before and after pancreatic duct drainage procedures (PDDP) with dynamic secretin-enhanced magnetic resonance (MR) cholangiopancreatography (S-MRCP). Pancreatic exocrine secretions [quantified by pancreatic flow output (PFO) and total excreted volume (TEV)] were quantified twice in ten healthy volunteers and before and after treatment in 20 CP patients (18 classified as severe, one as moderate, and one as mild according to the Cambridge classification). PFO and TEV were derived from a linear regression between MR-calculated volumes and time. In all subjects, pancreatic exocrine fluid volume initially increased linearly with time during secretin stimulation. In controls, the mean PFO and TEV were 6.8 ml/min and 97 ml; intra-individual deviations were 0.8 ml/min and 16 ml. In 10/20 patients with impaired exocrine secretions before treatment, a significant increase of PFO and TEV was observed after treatment (P<0.05); 3/20 patients presented post-procedural acute pancreatitis and a reduced PFO. The S-MRCP quantification method used in the present study is reproducible and provides normal values for PFO and TEV in the range of those obtained from previous published intubation studies. The initial results in CP patients have demonstrated non-invasively a significant short-term improvement of PFO and TEV after PDDP.
Bali
M A
MA
Department of Radiology, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik, 808, 1070, Brussels, Belgium. mbali@ulb.ac.be
Sztantics
A
A
Metens
T
T
Arvanitakis
M
M
Delhaye
M
M
Devière
J
J
Matos
C
C
D000328:Adult; D000368:Aged; D049448:Cholangiopancreatography, Magnetic Resonance; D004322:Drainage; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D046790:Pancreas, Exocrine / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D010183:Pancreatic Ducts / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D010186:Pancreatic Function Tests; D010189:Pancreatic Juice / Q000378:metabolism; D050500:Pancreatitis, Chronic / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000378:metabolism; D011446:Prospective Studies; D011857:Radiographic Image Interpretation, Computer-Assisted; D012016:Reference Values; D015203:Reproducibility of Results; D012633:Secretin / Q000008:administration & dosage; D013997:Time Factors
D005765:Gastrointestinal Agents; D012633:Secretin